Disputes Between South Korean Local Drug Makers And Multinationals Increasing, Expected To Get Worse
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending free trade agreement gives multinationals 20 years of patent protection, a long wait to make generics.
You may also be interested in...
South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers
SEOUL - South Korean pharmaceutical companies are bracing for a tough time ahead if the governments of South Korea and the U.S. ratify a long-awaited Free Trade Agreement hammered out last year after eight rounds of negotiations between the two countries
Sanofi-Aventis Loses Patent Lawsuit In Korea Over Oxaliplatin
SHANGHAI - Sanofi-Aventis lost a patent lawsuit in South Korea, after the country's Supreme Court dismissed its appeal to nullify patents obtained by Korea-based Boryung Pharmaceutical for its generic drug for colorectal cancer, Boryung announced Oct. 20
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.